Master of Science in Clinical Psychopharmacology Program

UH Hilo > DKICP Home > Academics> MSCP

Director: Dr. Supakit Wongwiwatthananukit
Program Coordinator: Dr. Judi Steinman

Program Learning Outcomes

The program prepares students to treat patients in need of a combination of psychotherapy and pharmacotherapy for mental disorders. The program will have an impact on prescribing habits for mental health disorders, helping to improve patient care for Hawai`i residents and military personnel and their families.

Each learning outcome addresses at least one of the following eleven content areas:

  1. Integrating clinical psychopharmacology with the practice of psychology;
  2. Neuroscience;
  3. Nervous system pathology;
  4. Physiology and pathophysiology;
  5. Biopsychosocial and pharmacologic assessment and monitoring;
  6. Differential diagnosis;
  7. Pharmacology;
  8. Clinical psychopharmacology;
  9. Research;
  10. Professional, legal, ethical, and inter-professional issues; and
  11. Clinical practice.

Upon completing the MSCP program, successful students will be able to:

  1. define, identify and recognize key concepts of terminology in all content areas;
  2. review and explain at a high level of proficiency, both orally and in writing, the most current theories of the pathophysiology, etiology, signs and symptoms underlying mental health disorders and their psychopharmacologic treatment;
  3. choose the appropriate diagnosis and effectively apply psychopharmacological knowledge to resolve clinical psychopathological cases using “Subjective, Objective, Assessment and Planning” (SOAP) notes and case presentations, and differentiate mental disorders that are drug-induced or caused by somatic disease;
  4. analyze, interpret, integrate and evaluate pharmacologically-based clinical findings in psychological settings through literature review, class presentations and written analysis.
  5. Devise, formulate and plan medication therapy management specific to psychopathology, with an emphasis on drug selection based on relative efficacy for the disorder, adverse effect profiles, food and drug interactions, and pharmacokinetics, and determine appropriate pharmacologic assessment and monitoring;
  6. Demonstrate the ability to compare and contrast and interpret epidemiological, professional, legal and ethical findings in the clinical psychopharmacology literature and case presentations using information technology.

Contact Us

For additional information, please Contact Dr. Judi Steinman.